Üremik Ensefalopati ve Kanıta Dayalı Tedavi Bakım Uygulamaları

Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. The lancet. 2017;389(10075):1238-52.

Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The lancet. 2020;395(10225):709-33.

Hamed SA. Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies. Expert review of clinical pharmacology. 2019;12(1):61-90.

Meyer TW, Hostetter TH. Uremia. New England Journal of Medicine. 2007;357(13):1316-25.

Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. Jama. 2007;298(17):2038-47.

Murray AM, Bell EJ, Tupper DE, Davey CS, Pederson SL, Amiot EM, et al. The brain in kidney disease (BRINK) cohort study: design and baseline cognitive function. American Journal of Kidney Diseases. 2016;67(4):593-600.

Seifter JL, Samuels MA, editors. Uremic encephalopathy and other brain disorders associated with renal failure. Seminars in neurology; 2011: © Thieme Medical Publishers.

Barkovich A. Toxic and metabolic brain disorders. Pediatric neuroimaging. 2005:76-189.

Trenkwalder C, Allen R, Högl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases: a systematic review and new concept. Neurology. 2016;86(14):1336-43.

Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. The Lancet Neurology. 2014;13(8):823-33.

Drechsler C, Kalim S, Wenger JB, Suntharalingam P, Hod T, Thadhani RI, et al. Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease. Kidney international. 2015;87(6):1201-8.

Sandsmark DK, Messé SR, Zhang X, Roy J, Nessel L, Lee Hamm L, et al. Proteinuria, but not eGFR, predicts stroke risk in chronic kidney disease: chronic renal insufficiency cohort study. Stroke. 2015;46(8):2075-80.

Masson P, Webster AC, Hong M, Turner R, Lindley RI, Craig JC. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrology Dialysis Transplantation. 2015;30(7):1162-9.

Frasnelli JA, Temmel AF, Quint C, Oberbauer R, Hummel T. Olfactory function in chronic renal failure. American journal of rhinology. 2002;16(5):275-9.

Wali GM, Khanpet MS, Mali RV. Acute movement disorder with bilateral basal ganglia lesions in diabetic uremia. Annals of Indian Academy of Neurology. 2011;14(3):211.

Renard D, Castelnovo G, Taieb G, Verd A, Lionnet C, Labauge P. Bilateral basal ganglia lesions in a diabetic-uremic patient with dystonia. Acta neurologica belgica. 2011;111(2):166-7.

Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC. Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. Brain. 2006;129(6):1585-92.

Chillon JM, Massy ZA, Stengel B. Neurological complications in chronic kidney disease patients. Nephrology Dialysis Transplantation. 2016;31(10):1606-14.

Liabeuf S, Pepin M, Franssen CF, Viggiano D, Carriazo S, Gansevoort RT, et al. Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle? Nephrology Dialysis Transplantation. 2022;37(Supplement_2):ii33-ii44.

Van Dijck A, Van Daele W, De Deyn PP. Uremic encephalopathy. Miscellanea on encephalopathies–a second look InTech. 2012:23-38.

Hughes JR. Correlations between EEG and chemical changes in uremia. Electroencephalography and Clinical Neurophysiology. 1980;48(5):583-94.

Biasioli S, D'Andrea G, Feriani M, Chiaramonte S, Fabris A, Ronco C, et al. Uremic encephalopathy: an updating. Clinical nephrology. 1986;25(2):57-63.

Yoon J, Pahl M, Vaziri N. Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney international. 2007;71(2):167-72.

Iwafuchi Y, Okamoto K, Oyama Y, Narita I. Posterior reversible encephalopathy syndrome in a patient with severe uremia without hypertension. Internal Medicine. 2016;55(1):63-8.

Rosner MH, Husain-Syed F, Reis T, Ronco C, Vanholder R. Uremic encephalopathy. Kidney International. 2022;101(2):227-41.

Kim D, Lee I, Song C. Uremic encephalopathy: MR imaging findings and clinical correlation. American Journal of Neuroradiology. 2016;37(9):1604-9.

T atsumoto N, Fujisaki K, Nagae H, Ono-Fujisaki A, Kura-Nakamura N, Taniguchi M, et al. Reversible posterior leukoencephalopathy syndrome in a patient with severe uremic encephalopathy. Clinical nephrology. 2010;74(2):154-8.

Kang E, Jeon SJ, Choi SS. Uremic encephalopathy with atypical magnetic resonance features on diffusion-weighted images. Korean Journal of Radiology. 2012;13(6):808-11.

Olano CG, Akram SM, Bhatt H. Uremic encephalopathy. 2020.

Raskin N. Neurological complications of renal failure. Neurology and general medicine 2nd ed New York: Churchill Livingstone. 1995:303-19.

Nomoto K, Scurlock C, Bronster D. Dexmedetomidine controls twitch-convulsive syndrome in the course of uremic encephalopathy. Journal of clinical anesthesia. 2011;23(8):646-8.

Betjes MG. Uremia-associated ageing of the thymus and adaptive immune responses. Toxins. 2020;12(4):224.

Chapman CL, Johnson BD, Vargas NT, Hostler D, Parker MD, Schlader ZJ. Both hyperthermia and dehydration during physical work in the heat contribute to the risk of acute kidney injury. Journal of applied physiology. 2020;128(4):715-28.

Balestracci A, Ezquer M, Elmo ME, Molini A, Thorel C, Torrents M, et al. Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis. Pediatric nephrology. 2015;30:1873-8.

Prencipe MA, Del Giudice A, Di Giorgio G, Aucella F. Uremic encephalopathy in regular dialysis treatment: uremic stroke? Giornale Italiano di Nefrologia: Organo Ufficiale Della Societa Italiana di Nefrologia. 2014;31(2):gin/31.2. 9-gin/.2. 9.

Vanholder R. European Uremic Toxin Work Group (EUTox): Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934-43.

Popkov VA, Silachev DN, Zalevsky AO, Zorov DB, Plotnikov EY. Mitochondria as a Source and a Target for Uremic Toxins. International journal of molecular sciences. 2019;20(12):3094.

Perna AF, Di Nunzio A, Amoresano A, Pane F, Fontanarosa C, Pucci P, et al. Divergent behavior of hydrogen sulfide pools and of the sulfur metabolite lanthionine, a novel uremic toxin, in dialysis patients. Biochimie. 2016;126:97-107.

De Deyn PP, Vanholder R, Eloot S, Glorieux G, editors. Progress in uremic toxin research: guanidino compounds as uremic (neuro) toxins. Seminars in dialysis; 2009: Wiley Online Library.

Moe S, Sprague S. Uremic encephalopathy. Clinical nephrology. 1994;42(4):251-6.

Leong SC, Sirich TL. Indoxyl sulfate-review of toxicity and therapeutic strategies. Toxins. 2016;8(12):358.

Vaziri ND, editor Oxidative stress in uremia: nature, mechanisms, and potential consequences. Seminars in nephrology; 2004: Elsevier.

Oshima N, Onimaru H, Matsubara H, Uchida T, Watanabe A, Takechi H, et al. Uric acid, indoxyl sulfate, and methylguanidine activate bulbospinal neurons in the RVLM via their specific transporters and by producing oxidative stress. Neuroscience. 2015;304:133-45.

Watanabe K, Sato E, Mishima E, Watanabe M, Abe T, Takahashi N, et al. Effect of uremic toxins on hippocampal cell damage: Analysis in vitro and in rat model of chronic kidney disease. Heliyon. 2021;7(2).

Adesso S, Magnus T, Cuzzocrea S, Campolo M, Rissiek B, Paciello O, et al. Indoxyl sulfate affects glial function increasing oxidative stress and neuroinflammation in chronic kidney disease: interaction between astrocytes and microglia. Frontiers in pharmacology. 2017;8:370.

Adesso S, Paterniti I, Cuzzocrea S, Fujioka M, Autore G, Magnus T, et al. AST-120 reduces neuroinflammation induced by indoxyl sulfate in glial cells. Journal of clinical medicine. 2018;7(10):365.

Lin YT, Wu PH, Tsai YC, Hsu YL, Wang HY, Kuo MC, et al. Indoxyl sulfate induces apoptosis through oxidative stress and mitogen-activated protein kinase signaling pathway inhibition in human astrocytes. Journal of Clinical Medicine. 2019;8(2):191.

Hsu HJ, Yen CH, Chen CK, Wu IW, Lee CC, Sun CY, et al. Association between uremic toxins and depression in patients with chronic kidney disease undergoing maintenance hemodialysis. General hospital psychiatry. 2013;35(1):23-7.

Bossola M, Ciciarelli C, Conte GL, Vulpio C, Luciani G, Tazza L. Correlates of symptoms of depression and anxiety in chronic hemodialysis patients. General hospital psychiatry. 2010;32(2):125-31.

Ting EYC, Yang AC, Tsai SJ. Role of interleukin-6 in depressive disorder. International journal of molecular sciences. 2020;21(6):2194.

Yamamoto T, Satomura K, Okada S, Ozono K. Risk factors for neurological complications in complete hemolytic uremic syndrome caused by Escherichia coli O157. Pediatrics International. 2009;51(2):216-9.

Malek M. Brain consequences of acute kidney injury: Focusing on the hippocampus. Kidney research and clinical practice. 2018;37(4):315.

Larson LM, Phiri KS, Pasricha SR. Iron and cognitive development: what is the evidence? Annals of Nutrition and Metabolism. 2017;71(Suppl. 3):25-38.

Day E, Bentham PW, Callaghan R, Kuruvilla T, George S. Thiamine for prevention and treatment of Wernicke‐Korsakoff Syndrome in people who abuse alcohol. Cochrane Database of Systematic Reviews. 2013(7).

Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. Journal of the American Society of Nephrology. 2002;13(4):1017-24.

Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, et al. Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl. Kidney international. 2005;67(2):760-71.

Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA, editors. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clinic Proceedings; 2010: Elsevier.

Bartynski W. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. American Journal of Neuroradiology. 2008;29(6):1043-9.

Battaglia F, Quartarone A, Bagnato S, Rizzo V, Morgante F, Floccari F, et al. Brain dysfunction in uremia: a question of cortical hyperexcitability? Clinical neurophysiology. 2005;116(7):1507-14.

Schmidt M, Sitter T, Lederer SR, Held E, Schiffl H. Reversible MRI changes in a patient with uremic encephalopathy. Journal of nephrology. 2001;14(5):424-7.

Brouns R, De Deyn P. Neurological complications in renal failure: a review. Clinical neurology and neurosurgery. 2004;107(1):1-16.

Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine. 2006;355(20):2071-84.

KDIGO. (2020). KDIGO 2020 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International Supplements, 99(3), S1–S87. https://kdigo.org/guidelines/

Rosner MH, Husain-Syed F, Reis T, Ronco C, & Vanholder R. Uremic encephalopathy. Kidney International. 2022;101(2): 227-241.

Olano, Claudia G., et al. "Uremic encephalopathy." StatPearls [Internet]. StatPearls Publishing, 2024.

Laville SM, Massy ZA, Kamel S, Chillon JM, Choukroun G, Liabeuf S. Intestinal chelators, sorbants, and gut-derived uremic toxins. Toxins. 2021;13(2):91.

Bell S, Kolobova I, Crapper L, Ernst C. Lesch-Nyhan syndrome: models, theories, and therapies. Molecular syndromology. 2016;7(6):302-11.

Singh JA, Cleveland JD. Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis. Arthritis Research & Therapy. 2018;20:1-9.

Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney international. 2013;83(6):1010-6.

Koşar Şahin, C., Ceylan H., & Yangöz Ş. T. (2024). Association between prebiotic or probiotic consumption and risk of type 2 diabetes mellitus in the general adult population. UHS Journal of Nursing, 6(2), 141-148. doi: 10.48071/sbuhemsirelik.1430172